Skip to content
AnalystLens

Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2026

Filing Date
Filed November 2, 2026
Period End
September 30, 2026
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-Q filed November 2, 2026. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported third-quarter 2026 total revenues of $1,122.7 milliona, up from $794.9 million a year earlier, with net product sales of $1,119.0 million.

Net income was $206.5 millionb, or $1.96 per diluted share, compared with $209.5 million, or $2.04 per diluted share, in the third quarter of 2025. For the first nine months of 2026, total revenues were $2,896.2 million and net income was $548.8 million, or $5.26 per diluted share. The period was shaped by the May 18, 2026 acquisition of Soleno Therapeutics, Inc., which added VYKAT XR.

The preliminary consideration transferred was $2,829.9 millionc, including $2,762.5 million paid to Soleno stockholders, and the acquisition produced $2,191.0 million of net intangible assets and $500.6 million of goodwill. Soleno contributed $106.7 million of net revenues in the third quarter and $161.1 million from the acquisition date through September 30, 2026, and a net loss of $35.1 million over that later period. Product sales growth was driven by CRENESSITY, with third-quarter net sales of $210.8 million versus $98.1 million a year earlier, and by INGREZZA, with third-quarter net sales of $801.5 million versus $686.6 million.

Operating expenses rose sharply, with research and development at $351.8 milliond and selling, general, and administrative expenses at $366.3 million in the quarter. Cash and cash equivalents were $641.5 million at September 30, 2026, and cash flows from operating activities were $677.4 million for the nine months. Cash, cash equivalents and marketable securities totaled $789.7 million, down from $2,543.4 million at December 31, 2025, reflecting the acquisition.

The company borrowed and repaid $600.0 million under a new $1.0 billion revolving credit facility, and $1.0 billion of borrowing capacity was available at quarter end. The filing also discloses risks that investors should weigh. A Paragraph IV ANDA filing by Alvogen against VYKAT XR was received in September 2026, and the company sued in October 2026, which triggers a statutory 30-month stay of approval.

The FDA identified fluid retention as a potential safety signal for VYKAT XR in a quarterly report published in September 2026. The Department of Justice is investigating INGREZZA sales and marketing, and a securities class action against Soleno is pending. The company repurchased $158.1 million of common stock in the first nine months, with $174.2 million remaining under its 2025 Repurchase Program.

Key Highlights

  1. Total revenues for Q3 2026 were $1,122.7 million, up from $794.9 million in Q3 2025; nine-month revenues were $2,896.2 million, up from $2,055.0 million.
  2. Net income was $206.5 million in Q3 2026 versus $209.5 million in Q3 2025, and $548.8 million for the nine months versus $324.9 million; diluted EPS was $1.96 for the quarter and $5.26 for the nine months.
  3. CRENESSITY net product sales reached $210.8 million in Q3 2026 versus $98.1 million a year earlier, and INGREZZA net product sales reached $801.5 million versus $686.6 million.
  4. The Soleno acquisition closed May 18, 2026 for preliminary consideration of $2,829.9 million, adding VYKAT XR and recording $2,191.0 million of net intangible assets and $500.6 million of goodwill; Soleno contributed $106.7 million of Q3 net revenues.
  5. Cash and marketable securities fell to $789.7 million at September 30, 2026 from $2,543.4 million at December 31, 2025, and a $1.0 billion revolving credit facility remains undrawn with $1.0 billion available.
  6. A Paragraph IV ANDA filed by Alvogen against VYKAT XR was disclosed, with a suit filed in October 2026 triggering a 30-month stay of approval; the FDA also identified fluid retention as a potential safety signal for VYKAT XR.
  7. The company is cooperating with a U.S. Department of Justice civil investigative demand regarding INGREZZA sales and marketing, with no assurance as to timing or outcome.

Financial Statements

Q3 FY2026 against Q3 FY2025

Line itemQ3 FY2026Q3 FY2025Change
Revenue$1.12B$794.90M+41.2%
SG&A Expenses$366.30M$291.60M+25.6%
Operating Expenses$791.40M$555.90M+42.4%
Operating Income$331.30M$239.00M+38.6%
Net Income$206.50M$209.50M−1.4%
EPS (Basic)$2.03$2.11−3.8%
EPS (Diluted)$1.96$2.04−3.9%
Shares Outstanding (Basic)101.60M99.40M+2.2%
Shares Outstanding (Diluted)105.20M102.50M+2.6%

Frequently Asked Questions

  1. How did revenue and profitability change in the third quarter of 2026?

    Total revenues rose to $1,122.7 million from $794.9 million, driven mainly by CRENESSITY and INGREZZA net product sales and the inclusion of VYKAT XR. Net income was slightly lower at $206.5 million compared with $209.5 million, reflecting higher operating expenses, a $52.3 million unrealized loss on equity investments, and a higher amortization charge of $35.0 million.

  2. What did the Soleno acquisition add to the company's financials?

    The company acquired Soleno Therapeutics on May 18, 2026 for preliminary consideration of $2,829.9 million, which recognized $2,191.0 million of net intangible assets for VYKAT XR developed product rights and $500.6 million of goodwill. Soleno contributed $106.7 million of net revenues in the third quarter and a net income of $17.1 million for that quarter, while its results from the acquisition date through September 30, 2026 showed a net loss of $35.1 million.

  3. How is the company's liquidity position after the acquisition?

    Cash and cash equivalents were $641.5 million and total cash, cash equivalents and marketable securities were $789.7 million at September 30, 2026, down from $2,543.4 million at December 31, 2025. The company repaid the $600.0 million it borrowed under its 2026 Credit Facility in June 2026, and $1.0 billion of borrowing capacity remained available at quarter end. Management believes existing resources and the facility will be sufficient for at least the next 12 months.

  4. What legal and regulatory risks does the filing highlight?

    The filing discloses a Paragraph IV ANDA from Alvogen against VYKAT XR, which the company is challenging in court, and a potential FDA safety signal for fluid retention with VYKAT XR. It also notes a Department of Justice civil investigative demand concerning INGREZZA sales and marketing, a securities class action against Soleno with a motion to dismiss pending, and an FDA untitled letter concerning INGREZZA promotional claims that the FDA later considered closed.

  5. How much has the company returned to shareholders?

    The company repurchased 1.1 million shares for $158.1 million in the first nine months of 2026, including 0.6 million shares for $92.1 million in the third quarter. As of September 30, 2026, $174.2 million remained available under the 2025 Repurchase Program, which was authorized at $500.0 million in February 2025.